CHESS1801
Research type
Research Study
Full title
Magnetically Controlled Capsule Endoscopy for Assessing Risk of Gastroesophageal Varices Bleeding in Compensated Liver Cirrhosis (CHESS1801): A Prospective Multicenter Study
IRAS ID
262624
Contact name
Mark McAlindon
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS FT
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 4 months, 8 days
Research summary
Gastroesophageal varices occurs in approximately half of the patients with liver cirrhosis. Variceal bleeding is the most common lethal complication directly from cirrhotic portal hypertension. The gold standard for diagnosing gastroesophageal varices and evaluating the risk of variceal bleeding is the esophagogastroduodenoscopy. According to the Baveno VI consensus, for those with high-risk varices (varies needing treatment), either non-selective beta blockers or endoscopic band ligation is recommended for the prevention of the first variceal bleeding. However, the invasiveness and uncomfortableness during the esophagogastroduodenoscopy procedure has hindered its use in clinical practice, especially in patients with compensated liver cirrhosis.
Magnetically controlled capsule endoscopy, as an emerging non-invasive technique, has been well established and shown the comparable accuracy for detection of focal lesions in the stomach compared with conventional esophagogastroduodenoscopy. In the present study, the investigators aim to conduct a prospective, multi-center diagnostic trial with 18 sites in China and 1 in the UK to further evaluate the diagnostic performance of magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.) for assessing risk of gastroesophageal varices bleeding in compensated liver cirrhosis.
REC name
South Central - Hampshire B Research Ethics Committee
REC reference
19/SC/0260
Date of REC Opinion
2 Jul 2019
REC opinion
Further Information Favourable Opinion